China Medicine Sector Growth Led All Others At Beginning Of Year
This article was originally published in PharmAsia News
Executive Summary
The medical industry in China outshone all other sectors in the first two months of this year despite being dragged down somewhat by slower export activity. The Ministry of Industry and Information Technology said biomedicine profits during the period increased by 21.1 percent over a year ago and those of chemical medicine by 14 percent. Traditional Chinese medicine grew by 20.4 percent. The medicine sector growth was hampered somewhat by a growth of only 3 percent in exports, compared with 17.4 percent registered a year ago. (Click here for more
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.